Form 4: Xeris Biopharma Director Sells 15,000 Shares

Xeris Biopharma Holdings, Inc. Director Barbara-Jean Anne Bormann-Kennedy sold 15,000 shares of common stock for approximately $7.09 per share under a Rule 10b5-1 plan.

Summary

• Director Barbara-Jean Anne Bormann-Kennedy of Xeris Biopharma Holdings, Inc. (XERS) reported a sale of common stock.
• The transaction involved the disposition of 15,000 shares of common stock.
• The shares were sold at a weighted average price of $7.0943 per share.
• Individual sale prices ranged from $7.000 to $7.180.
• The transaction was executed on December 12, 2025.
• Following this transaction, Barbara-Jean Anne Bormann-Kennedy directly owns 142,500 shares of common stock.
• The sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can sometimes be viewed negatively, the transaction was conducted under a Rule 10b5-1 plan, which suggests a pre-planned diversification or liquidity event rather than a reaction to new negative information. The remaining beneficial ownership is still substantial.

Negatives

• A director selling a significant number of shares (15,000) could be perceived negatively by some investors, potentially signaling a lack of confidence or a desire to diversify holdings.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects an individual director's portfolio management decision rather than a company-wide strategic move.

Related Party Transactions

• Director Barbara-Jean Anne Bormann-Kennedy, a related party, sold 15,000 shares of Xeris Biopharma Holdings, Inc. common stock.

Stakeholder Impact

• Shareholders: May interpret the director's sale differently; some might see it as a routine diversification, while others might view it as a slight negative signal, though mitigated by the 10b5-1 plan.
• Employees, Customers, Suppliers, Creditors: Unlikely to have a direct impact from this specific insider transaction.

Key Dates

Recommendation

The sale by a director, while notable, was conducted under a pre-arranged Rule 10b5-1 plan, which typically indicates a planned liquidity event or portfolio diversification rather than a reaction to new material information. The remaining beneficial ownership is still significant. Without additional context from other filings or market conditions, this single transaction does not warrant a change from a 'hold' position, as it doesn't fundamentally alter the company's operational or financial outlook.

Keywords

Xeris Biopharma Holdings, XERS, Form 4, Insider Sale, Director Transaction, Stock Sale, Rule 10b5-1, Barbara-Jean Anne Bormann-Kennedy